scholarly journals Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy

Cancer ◽  
1986 ◽  
Vol 57 (7) ◽  
pp. 1327-1329 ◽  
Author(s):  
Hannu Halila ◽  
Ulf-H??kan Stenman ◽  
Markku Seppälä
Keyword(s):  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
Ca 125 ◽  
Cancer Antigen

scholarly journals Erroneously Suspected Ovarian Cancer in a 38-Year-Old Woman with Pelvic Inflammatory Disease and Chlamydia

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Romana Brun ◽  
Juliane Hutmacher ◽  
Daniel Fink ◽  
Patrick Imesch
Keyword(s):  
Ovarian Cancer ◽  
Ct Scan ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
Transmitted Disease ◽  
Young Patients ◽  
Chlamydia Infection ◽  
Ca 125 ◽  
Abdominal Sonography ◽  
Sexually Transmitted

Chlamydia trachomatis is the most common bacterial cause of sexually transmitted disease and can cause pelvic inflammatory disease (PID), leading to severe outcomes such as ectopic pregnancy, infertility, or pelvic pain. We report a case of a 38-year-old patient with abdominal pain and dyspareunia. Clinical examination revealed diffuse abdominal tenderness. Vaginal and abdominal sonography showed substantial ascites and CA-125 level was elevated. Therefore, the attendant physician performed an abdominal CT scan for further diagnosis. Radiographically diffuse peritoneal enhancement, consistent with peritoneal carcinomatosis, 4-quadrant ascites, and slightly enlarged ovaries with solid and cystic structures were diagnosed, leading to the suspicion of ovarian cancer. In addition, the results of the cervical smear PCR for chlamydia were positive. Due to the positive chlamydia result, the suspicious CT scan, and the young age, we decided to perform a diagnostic laparoscopy as a first step. Intraoperatively, the ovaries were of normal aspect without any cancerous lesions. However, the ascites and the yellow-reddish jelly-like deposits were consistent with acute PID. Thus, chlamydia infection may simulate the presentation of ovarian cancer. Therefore, especially in young patients, we recommend careful scrutiny of every diagnosis of ovarian cancer even if its presentation seems to be typical.

Serum HE4 as a Useful Biomarker in Discriminating Ovarian Cancer From Benign Pelvic Disease

2012 ◽  
Vol 22 (6) ◽  
pp. 1000-1005 ◽  
Author(s):  
Hong Zheng ◽  
Yunong Gao
Keyword(s):  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
Area Under The Curve ◽  
Pelvic Mass ◽  
Secretory Protein ◽  
Ca 125 ◽  
Serum Samples ◽  
Ovarian Endometriosis ◽  
Premenopausal Patients

ObjectiveTo evaluate the role of the novel tumor marker human epididymal secretory protein E4 (HE4) in discriminating ovarian cancer from benign pelvic disease in patients with a pelvic mass.MethodsSerum samples from 131 patients with epithelial ovarian cancer (EOC) and 126 patients with various benign pelvic diseases were collected preoperatively and tested for cancer antigen (CA)125 and HE4 levels. Receiver operator characteristic curves were constructed, and the area under the curve (AUC) was compared between the markers.ResultsThe median CA125 and HE4 levels were significantly higher in the patients with EOC than in those with benign disease (P < 0.001). Using benign controls as the comparison group for all cases, the AUC for combined HE4 and CA125 (0.955) was significantly higher than that for HE4 (0.941) or CA125 alone (0.924; P < 0.05). A comparison of premenopausal benign controls to EOC cases showed that the AUC for combined HE4 and CA125 (0.97) was significantly higher than that for CA125 (0.93; P < 0.004). The AUC for HE4 was significantly higher compared to that of CA125 in discriminating EOC from ovarian endometriosis (0.969 vs 0.904; P = 0.014) and pelvic inflammatory disease (0.909 vs 0.819; P = 0.034).ConclusionSerum HE4 testing is a more powerful tool than CA125 assay to discriminate EOC from ovarian endometriosis and pelvic inflammatory disease. For patients with a pelvic mass, especially premenopausal patients, the serum concentration of HE4 adds valuable information to CA125 in identifying patients with EOC from those with benign pelvic disease.

scholarly journals Primary Fallopian Tube Carcinoma Arising in the Setting of Chronic Pelvic Inflammatory Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ibrahim M. Zardawi
Keyword(s):  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Chronic Inflammation ◽  
Fallopian Tube ◽  
Inflammatory Disease ◽  
Fallopian Tube Carcinoma ◽  
Fallopian Tube Cancer ◽  
Primary Fallopian Tube Carcinoma ◽  
Gynaecological Malignancy

Primary fallopian tube cancer (PFTC) is a rare gynaecological malignancy, clinically often mistaken for pelvic inflammatory disease or ovarian cancer. Three primary fallopian tube carcinomas, arising in a background of chronic pelvic inflammatory disease (PID), are presented. The possible association between chronic PID and PFTC is discussed and a hypothesies linking these cancers with chronic inflammation is proposed.

Ovarian cancer screening in the general population

2019 ◽  
Vol 41 (3) ◽  
Author(s):  
Jérôme Mathis ◽  
Mohammed Amine Jellouli ◽  
Laura Sabiani ◽  
Joy Fest ◽  
Guillaume Blache ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Screening ◽  
General Population ◽  
Ultrasound Examination ◽  
Screening Method ◽  
Diagnostic Technique ◽  
Ca 125 ◽  
Ovarian Cancer Screening ◽  
Cancer Antigen ◽  
Diagnostic Management

AbstractBackgroundOvarian carcinoma is a poor prognosis cancer mainly due to its late diagnosis. Its incidence is relatively low but mortality is high. The symptomatology is only slightly specific, which complicates diagnostic management. It would therefore be interesting to be able to establish a diagnosis as early as possible in order to improve the prognosis of patients suffering from ovarian cancer.Materials and methodsCurrently, the combination of an ultrasound examination with a cancer antigen (CA)-125 assay is the most effective diagnostic technique, but not already admitted as a screening method. Therefore, we realized an exhaustive analysis of the most important studies in the last 15 years, in order to find new approaches in ovarian cancer screening.ResultsThe age for initiating screening and its frequency are issues that are not fully resolved. The false positives and morbidity that result from screening are currently notable limitations.ConclusionsThe latest data do not support effective screening in the general population.

CA 125 in Benign Gynecological Conditions

1998 ◽  
Vol 13 (4) ◽  
pp. 231-237 ◽  
Author(s):  
H. Meden ◽  
A. Fattahi-Meibodi
Keyword(s):  
Tumor Marker ◽  
Ectopic Pregnancy ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
Cirrhosis Of The Liver ◽  
Ca 125 ◽  
Ovarian Cysts ◽  
Gynecological Tumors ◽  
Ovarian Abscess

The tumor marker CA 125 was initially thought to be specific for ovarian malignancies. Subsequently it was found to be raised in a variety of benign conditions, including pregnancy, pelvic inflammatory disease, tuberculosis and cirrhosis of the liver. With respect to gynecological tumors, CA 125 may be elevated in benign ovarian cysts, tubo-ovarian abscess, endometriosis, hyperstimulation syndrome, ectopic pregnancy and fibroids. These results demonstrate that CA 125 is a marker of non-specific peritoneal conditions.

scholarly journals Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer

2018 ◽  
Vol 55 ◽  
pp. 110-116 ◽  
Author(s):  
Louise M. Stewart ◽  
Katrina Spilsbury ◽  
Susan Jordan ◽  
Colin Stewart ◽  
C. D’Arcy J. Holman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
High Grade ◽  
Serous Ovarian Cancer

scholarly journals Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis

2017 ◽  
Vol 28 (5) ◽  
pp. 415-428 ◽  
Author(s):  
Zhiyi Zhou ◽  
Fangfang Zeng ◽  
Jianhui Yuan ◽  
Jinling Tang ◽  
Graham A. Colditz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Pelvic Inflammatory Disease ◽  
Inflammatory Disease ◽  
Meta Analysis

scholarly journals Immunohistochemical Study of CA 125 in Surface Epithelial Tumors of Ovary in Correlation with Serum Levels

2020 ◽  
Vol 7 (7) ◽  
pp. A355-360
Author(s):  
Karishma Pillarisetty ◽  
Savithri Ravindra
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Neoplasms ◽  
Serum Levels ◽  
Tissue Expression ◽  
Epithelial Differentiation ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Epithelial Tumors ◽  
Wide Range

Background: Ovarian carcinoma is the 4th leading cancer among women in India. Primary ovarian neoplasms exhibit a wide range of histopathological patterns and tumors with epithelial differentiation are most frequent. Among malignant tumors, most common histological type is serous adenocarcinoma whose diagnosis is established in advanced stages of disease in approximately 75% of patients. The most widely used tumor marker in ovarian cancer, often considered “gold standard” is Cancer Antigen125. Cancer Antigen 125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with advanced epithelial ovarian cancer.   Methods: A 2 year prospective study included 81 cases of ovarian neoplasms with surface epithelial differentiation.  The specimens were fixed in 10% formalin, routinely processed. Sections of 4-5 microns thickness were obtained from the paraffin block and stained with Hematoxylin & Eosin. The tumors were categorised according to WHO classification.  Immunohistochemical analysis of Cancer Antigen 125 was done in all malignant & borderline tumors.   Result: A total of 81 cases were studied. There were 15 cases with elevated serum Cancer Antigen 125 levels. Of these 8 showed positive tissue expression. The sensitivity of serum Cancer Antigen 125 was 68.75% & its specificity was 93.8%.   Conclusion: Serum Cancer Antigen 125 is elevated in ovarian tumors especially in malignant surface epithelial tumors & more commonly in serous cystadenocarcinoma. There was a good correlation between serum levels & tissue expression of Cancer Antigen 125.

Sign in / Sign up

Export Citation Format

Share Document